Ghana Starts Clinical Trial for Lassa Fever Vaccine
Researchers are testing a new vaccine candidate designed to prevent outbreaks of the viral disease in West Africa.
Updated on Oct. 22, 2026 in COVID-19
Live Poll
Should regional governments prioritize development of vaccines for diseases not currently present in their country?
Ghana has launched a clinical trial for an experimental Lassa fever vaccine, the ChAdOx1 LassaJ, to evaluate its safety and immune response. This initiative aims to address a critical health gap as there is currently no licensed vaccine for the disease.
Why it matters
Researchers hope to prepare for potential outbreaks caused by regional human movement between Ghana and neighboring countries where the virus is prevalent. Mathematical models suggest a successful vaccine could save thousands of lives and reduce significant societal costs over the next decade.
The clinical trial is testing the ChAdOx1 LassaJ vaccine on 51 healthy adults aged 18 to 55 to assess its safety profile. Projections suggest a vaccine could save 3,300 lives and prevent 128 million dollars in societal costs over 10 years.
The players
University of Oxford
This prestigious academic institution is leading the research and development of the ChAdOx1 LassaJ vaccine candidate.
CEPI
The Coalition for Epidemic Preparedness Innovations is an international partnership that provided 24.9 million dollars to fund this vaccine research.
Kintampo Health Research Centre
This facility is located in Ghana's Bono East Region and serves as the primary site for conducting the vaccine clinical trial.
The details
Administered at the Kintampo Health Research Centre, the trial utilizes the ChAdOx1 technology platform to measure how the human body reacts to the candidate vaccine. A parallel study is currently underway in the United Kingdom as part of the broader research effort.
Timeline
Lassa fever was first identified in 1969 in Lassa, Nigeria.
The clinical trial in Ghana officially began on October 14, 2026.
The Big Picture
This trial leverages the ChAdOx1 technology platform to address a long-standing medical challenge in West Africa. It follows the established application of this platform, which was most notably utilized in the development of COVID-19 vaccines.
While the trial is currently limited to 51 healthy adult participants, successful results could eventually provide a life-saving preventative measure for residents in high-risk regions. There are no immediate changes to treatment options or vaccine availability for the general public at this stage.
The takeaway
Lassa fever remains a significant health threat in West Africa with no currently licensed vaccine to prevent its spread. This research represents an important step in building regional health security and reducing the long-term societal burden of the virus.
Further reading
Learn more about vaccine development and disease prevention in our COVID-19 section.
Live Poll
Should regional governments prioritize development of vaccines for diseases not currently present in their country?
